Giggles N’ Hugs Rights Offering Subscription Period Scheduled to Expire
Mar 28, 2018 20:11 pm UTC| Business
Los Angeles, March 28, 2018 -- Giggles N’ Hugs, Inc. (OTCQB: GIGL) (the “Company”), owner and operator of family-friendly restaurants that bring together high-end, organic food with active, cutting-edge play and...
HealthEquity Appoints New Director to the Board
Mar 28, 2018 20:07 pm UTC| Business
DRAPER, Utah, March 28, 2018 -- HealthEquity, Inc. (NASDAQ:HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (HSA) non-bank custodian, today announced that its Board of Directors has...
Sunworks Announces Appointment of Renewable Energy Expert to Board of Directors
Mar 28, 2018 20:07 pm UTC| Business
ROSEVILLE, Calif., March 28, 2018 -- Sunworks, Inc. (Nasdaq:SUNW), a premier provider of high performance solar power solutions for agriculture, commercial, industrial (ACI), public works and residential markets, today...
Mar 28, 2018 20:06 pm UTC| Business
Acquisition and additional funding significantly accelerate the company’stransformation to a specialty biopharmaceutical company with the potential tocommercialize two ophthalmic products in 1H 2019 Icon Bioscience’s...
Mar 28, 2018 20:06 pm UTC| Business
HOUSTON, March 28, 2018 -- Deep Down, Inc. (OTCQX:DPDW), a specialist in deepwater oil and gas production and distribution equipment and services, today reported financial results for the fourth quarter (Q4 ’17) and...
Worthington Industries Declares Quarterly Dividend
Mar 28, 2018 20:05 pm UTC| Business
COLUMBUS, Ohio, March 28, 2018 -- The board of directors of Worthington Industries, Inc. (NYSE:WOR) has declared a quarterly dividend of $0.21 per share. The dividend is payable on June 29, 2018, to shareholders of...
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Mar 28, 2018 20:05 pm UTC| Business
BERKELEY HEIGHTS, N.J., March 28, 2018 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") a biopharmaceutical company developing oral therapies that target the various phases of...